{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:45:19Z","timestamp":1787312719527,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"EpiEndo Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pupt.2025.102365","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T02:48:48Z","timestamp":1748918928000},"page":"102365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial"],"prefix":"10.1016","volume":"90","author":[{"given":"Jens M.","family":"Hohlfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Badorrek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hanrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Parnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pupt.2025.102365_bib1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(20)30080-1","article-title":"Immunomodulation by macrolides: therapeutic potential for critical care","volume":"8","author":"Reijnders","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.pupt.2025.102365_bib2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2025.102365_bib3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.pupt.2025.102365_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1753465816682677","article-title":"Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease","volume":"11","author":"Qiu","year":"2017","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"5","key":"10.1016\/j.pupt.2025.102365_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S2213-2600(14)70087-6","article-title":"Azithromycin for patients with frequent COPD exacerbations","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"Suppl. 66","key":"10.1016\/j.pupt.2025.102365_bib6","first-page":"312","article-title":"Inhibition of neutrophilic inflammation by targeting the airway epithelial barrier with EP395","volume":"60","author":"Kricker","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"Suppl. 68","key":"10.1016\/j.pupt.2025.102365_bib7","article-title":"The new macrolide EP395 reduces airway eosinophilic inflammation","volume":"64","author":"Kricker","year":"2024","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2025.102365_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2466-13-19","article-title":"Low-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development","volume":"13","author":"Janssen","year":"2013","journal-title":"BMC Pulm. Med."},{"issue":"6","key":"10.1016\/j.pupt.2025.102365_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.pupt.2006.08.002","article-title":"Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human","volume":"20","author":"Michel","year":"2007","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.pupt.2025.102365_bib10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(13)70187-5","article-title":"Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials","volume":"1","author":"Franciosi","year":"2013","journal-title":"Lancet Respir. Med."},{"issue":"10","key":"10.1016\/j.pupt.2025.102365_bib11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00228-015-1920-1","article-title":"Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects","volume":"71","author":"Singh","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.pupt.2025.102365_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/thoraxjnl-2017-210305","article-title":"Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury","volume":"73","author":"Proudfoot","year":"2018","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.pupt.2025.102365_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/s41598-024-51547-0","article-title":"Transcriptomic characterization of the human segmental endotoxin challenge model","volume":"14","author":"Gress","year":"2024","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.pupt.2025.102365_bib14","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/jac\/dkm084","article-title":"Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin","volume":"59","author":"Shinkai","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pupt.2025.102365_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/pharmrev.121.000300","article-title":"Nonantimicrobial actions of macrolides: overview and perspectives for future development","volume":"73","author":"Kricker","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pupt.2025.102365_bib16","first-page":"50","article-title":"Inter-and intrasubject variability of the inflammatory response to segmental endotoxin challenge in healthy volunteers Pulmonary","volume":"235","author":"Holz","year":"2015","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2025.102365_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2023.1239151","article-title":"Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease","volume":"14","author":"Chalmers","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pupt.2025.102365_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox11112302","article-title":"Regulation of neutrophil function and target for therapy","volume":"11","author":"Rizo-T\u00e9llez","year":"2022","journal-title":"Antioxidants"},{"issue":"16","key":"10.1016\/j.pupt.2025.102365_bib19","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMe2500787","article-title":"Defanging the neutrophil to treat bronchiectasis","volume":"392","author":"Hill","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pupt.2025.102365_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imr.12577","article-title":"Alarmins and immunity","volume":"280","author":"Yang","year":"2017","journal-title":"Immunol. Rev."},{"issue":"16","key":"10.1016\/j.pupt.2025.102365_bib21","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DDP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2025.102365_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.01551-2024","article-title":"Cathepsin C (dipeptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose finding study","volume":"65","author":"Chalmers","year":"2025","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.pupt.2025.102365_bib23","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"Suppl. 68","key":"10.1016\/j.pupt.2025.102365_bib24","article-title":"A novel macrolide EP395 in patients with stable COPD: an RCT","volume":"64","author":"Watz","year":"2024","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2025.102365_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2025.102365_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0014-2999(01)01321-8","article-title":"Anti-inflammatory effects of macrolide antibiotics","volume":"429","author":"Culic","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pupt.2025.102365_bib27","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"issue":"Suppl. 68","key":"10.1016\/j.pupt.2025.102365_bib28","article-title":"Effect of azithromycin treatment on epithelial antiviral immunity in patients with uncontrolled asthma (AZIMUNE-study)","volume":"64","author":"Ghanizada","year":"2024","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2025.102365_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fmed.2018.00018","article-title":"Surfactant protein D in respiratory and non-respiratory diseases","volume":"5","author":"Sorensen","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.pupt.2025.102365_bib30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41423-022-00946-2","article-title":"Surfactant protein D inhibits lipid-laden foamy macrophages and lung inflammation in chronic obstructive pulmonary disease","volume":"20","author":"Hsieh","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.pupt.2025.102365_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.apha.2023.03.002","article-title":"Prospects for macrolide therapy of asthma and COPD","volume":"98","author":"Parnham","year":"2023","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pupt.2025.102365_bib32","article-title":"Low levels of exhaled surfactant protein A associated with BOS after lung transplantation","volume":"2","author":"Ericson","year":"2016","journal-title":"Trans. Direct."},{"key":"10.1016\/j.pupt.2025.102365_bib33","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.healun.2007.08.009","article-title":"Bronchoalveolar lavage fluid proteome in bronchiolitis obliterans syndrome: possible role for surfactant protein A in disease onset","volume":"26","author":"Meloni","year":"2007","journal-title":"J. Heart Lung Transplant."},{"issue":"Suppl 58","key":"10.1016\/j.pupt.2025.102365_bib34","article-title":"Beneficial effect of azithromycin in children with diffuse parenchymal lung disease","volume":"44","author":"Perisson","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2025.102365_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-009988","article-title":"Diffuse parenchymal lung disease caused by surfactant deficiency: dramatic improvement by azithromycin","author":"Thouvenin","year":"2013","journal-title":"BMJ Case Rep."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553925000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553925000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:01:14Z","timestamp":1756900874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553925000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"alternative-id":["S1094553925000227"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2025.102365","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2025.102365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102365"}}